Neuromuscular Blocking Agents in Cardiac Surgery

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

39 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-11-05

Study Completion Date

2025-05-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Background:

Neuromuscular blocking agents (NMBA) are commonly used in cardiac surgery anesthesia to facilitate airway management and ventilation, and ensure optimal operative conditions. To improve post-operative results and reduce the length of stay in the intensive care unit, the concept of "Fast track anesthesia" is coming into force, which includes all techniques that offer extubation within 1-6 hours post-operatively. Fast-track cardiac surgery is only feasible when short-acting NMBA are used and neuromuscular transmission has returned to normal by the end of the operation or just before extubation, a few hours after surgery. This requires quantitative monitoring of muscle strength, the only way to eliminate residual paralysis defined by a TOF ratio ≥ 0.9. The American Society of Anesthesiologists (ASA) and the European Society of Anesthesiology and Intensive Care (EASIC) recommend quantitative measurement of neuromuscular block until extubation.This is the only way to avoid the complications of residual paralysis, essentially postoperative pulmonary complications. The POPULAR study clearly highlighted the shortcomings of current NMBA management: out of a total population of 17150 patients, only 16.5% were extubated, with a TOF ratio greater than 0.90. Cardiac surgery patients are brought to the ICU still sedated, intubated and ventilated. Neuromuscular blocking agents are usually discontinued at the end of surgery. As awakening and extubation take place later in the ICU, clinicians often consider that the action of neuromuscular blocking agents is over, but without making a quantitative measurement as recommended by the guidelines.
2. Objectives of the clinical research project:

2.1 Primary objective: The primary objective of this single-center prospective observational study is to systematically monitor the degree of postoperative curarization up to the time of extubation, and to assess the degree of adherence of intensive care teams to extubation recommendations based on quantitative measurements of the degree of neuromuscular junction block.

2.2 Secondary objectives: Quantify NMBA doses used, duration of action, duration of recovery.
3. Methodology of the clinical research project:

In this study, we will systematically check the degree of curarization of cardiac surgery patients up to the time of extubation. Prior to surgery, all patients will have an explanation of the protocol and will give written informed consent for the use of their data. Patient management is at the discretion of the anaesthetist in charge and will not be altered in any way by the protocol. All drugs used will be "standard of care". At the end of the procedure, one of the investigators will stay with the patient in intensive care and measure the degree of neuromuscular blockade with a curameter used as standard in clinical routine at Erasme Hospital (TOFScan, IdMed, Marseille, France). All measurements will be made in accordance with Good clinical research practice (GCRP) in pharmacodynamic studies of neuromuscular blocking agents III. This measurement will be carried out continuously until the patient is extubated or 100% neuromuscular transmission has been recovered. ICU staff in charge of the patient will be blinded to the measurements done by the investigators. Intensive care physicians manage the patient according to the ICU standard of care. If the patient represents a residual curarization at the time of extubation, the investigators will inform the ICU staff in order to avoid endangering the patient.

No intervention will be made with regard to the anesthesia and post-operative monitoring protocol; all medications and interventions will be considered "standard of care" and will be left to the discretion of the anesthesiologist and ICU team in charge.
4. Design of the clinical research project:

This is a prospective, observational study.
5. Participants:

All patients undergoing cardiac surgery at Hôpital Érasme between October 1, 2024 and May 31, 2025.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Management of Neuromuscular Blocking Agents and Their Antagonism

NCT06238219

Neuromuscular Blocking Agents Neuromuscular Monitoring

RECRUITING

Influence of Neuromuscular Block on Mask Ventilation

NCT01849211

Effect of a Neuromuscular Block on Ventilation

COMPLETED NA

Impact of Deep Versus Standard Muscle Relaxation on Intra-operative Safety

NCT04124757

Neuromuscular Blockade Rocuronium Anesthetics +3 more

COMPLETED NA

Paraspinal Muscle Relaxation in Spine Surgery

NCT03318718

Paraspinal Muscle Relaxation in Spine Surgery

COMPLETED NA

Neuromuscular Blocking Agents in the Elderly

NCT03857750

Elective Surgery

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Surgery Neuromuscular Blocking Agents

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cardiac surgery with NMBA

All patients undergoing cardiac surgery at Hôpital Érasme between October 1, 2024 and May 31, 2025 who receive any neuromuscular blocking agent.

Neuromuscular blockade

Intervention Type DIAGNOSTIC_TEST

Neuromuscular blockade will be measured in all patients using a quantitative measurement (TOFScan, IdMed, Marseille, France) during surgery and after surgery until either full neuromuscular recovery or time of scheduled extubation.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neuromuscular blockade

Neuromuscular blockade will be measured in all patients using a quantitative measurement (TOFScan, IdMed, Marseille, France) during surgery and after surgery until either full neuromuscular recovery or time of scheduled extubation.

Intervention Type DIAGNOSTIC_TEST